April 19th 2024
The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Choosing Appropriate Patients and Dosing for Lenvatinib + Pembrolizumab in RCC
Expert insights on selecting the appropriate patients and dose for treatment with the lenvatinib plus pembrolizumab regimen in patients with renal cell carcinoma.
Patient Profile 1: Favorable-Risk RCC Treated With Lenvatinib + Pembrolizumab
Experts open their discussion on RCC by reviewing the clinical scenario of a patient with favorable-risk disease who is treated with the TKI/IO regimen of lenvatinib and pembrolizumab.